INTRODUCTION
During the past decade, research on the biology and regulation of the Hippo pathway gained impetus from pioneering Drosophila studies (1) (2) (3) (4) . Intensive research on Drosophila genetics has been instrumental for our current knowledge about the Hippo pathway (5-8). Many of these genes were in the Hippo pathway, suggesting that the Hippo plays a vital role in the development and growth of Drosophila (4, 9-12). In a recent study, the Hippo pathway functioned as a regulator of tissue growth that would be considered a tumor suppressor pathway of human cancer in neoplastic organs (8, 13-16). In addition, the growing body of evidence connecting YAP to cancer biology encourages the translation of preclinical findings into clinical research (13, (17) (18) (19) (20) . Therefore, in this review, we examine human carcinogenesis related to the Hippo pathway.
The Hippo pathway is a highly conserved regulator of organ size as well as of stem cell proliferation and maintenance (6, 14, 21). It regulates the Yes-associated protein -a co-transcriptional factor -in a negative manner. The Hippo core component, composed of the kinase MST1/2, LATS1/2, and the adaptor protein SAV1 inhibitively phosphorylates the Hippo pathway terminal downstream YAP (Fig. 1) . Mechanically, activated MST1/2 kinase associates with its scaffolding partners SAV1 and phosphorylate LATS1/2, resulting in a LAT1/2 activation (6, 8, 15). The activated LATS1/2 kinase then advances to phosphorylate YAP on the phosphorylation site, leading to the inactivation of YAP by cytoplasmic sequestering and degradation ( Fig. 1) (22, 23) . In case that the SAV1-MST1/2-LATS1/2 cascade axis is inactive, YAP can accumulate in the nucleus and function as co-transcription factors by interacting with the transcriptional enhancer factor (TEF) family of transcription factors (TEAD) (Fig.  1) (24) . The inactivation of the Hippo pathway could lead to excessive cell proliferation and the inhibition of apoptosis, resulting in tumorigenesis. It has been confirmed that the expression of YAP was increased in various organs of human cancer (14, 17, 19). Therefore, abnormal YAP expressions are strongly associated with the occurrence, development, and prognosis of cancers, which is a phenomenon that has become a favorite topic of cancer research.
For many years, the development of new effective therapies has progressed and dramatically improved survival rates (25-29). Nevertheless, it occurs even in significantly positive clinical responses to chemotherapeutic and targeted therapies that a complete remission is hardly durable, since almost all cancers acquire an anti-cancer drug resistance (17, 30-34) which can even be considered a key property of malignant growths. The drug resistance mechanisms are not fully understood, but they are particularly important in designing novel targeted therapies aimed at preventing this resistance (30, 35). To address this issue, we identify YAP as a key survival input that mediates drug resistance in parallel to several known independent pathways of tumorigenesis (17, 36-47).
PART 1. YAP IN HUMAN CANCER
The analysis of clinical-pathological and biological results demonstrates that the increased activation and expression of YAP was correlated with the stage and prognoses of tumors (42, 44, (47) (48) (49) (50) (51) (52) (53) (54) (55) . Specifically, these current views about the Hippo pathway are consistent with numerous previous studies reporting that a YAP activation or expression corresponds to cancer evolution and progression (14, (18) (19) (20) 56) . Thus, we suggest that the YAP -as a potential oncogene -is a promising independent prognostic biomarker of various cancers.
Lung cancer
Lung cancer includes several subtypes, including lung adenocarcinomas (LACs), lung squamous cell carncinomas (LSCCs), and large-cell lung carcinomas, which are all generally defined as non-small-cell lung cancers (NSCLCs). NSCLCs are responsible for most mortalities among cancers (57) (58) (59) . Recent clinical research reported that the expressions or nuclear staining of YAP were elevated in NSCLCs (14, 39, 60, 61). A hyper-activation of the YAP level was associated with an overall shorter patient survival rate. NSCLC immunohistochemistry found that a YAP up-regulation is relevant for a high histology score, the lung cancer stage, metastases, and a poor cancer progression. The increased expression of YAP target genes correlated with a poor disease progression as evidenced in a cancer database of NSCLC patients (14, 39, 42, 55) . In addition, Chaeuk chung groups reported that an elevated YAP in NSCLC specimens obtained from the development of acquired EGFR inhibitors resistance (60, 61) . Among seven cases, six drug-resistant patients exhibited increased nuclear YAP staining as compared with their baseline. Additionally, they and other groups showed that the combination therapy of an EGFR inhibitor and a YAP inhibitor overcame the EGFR inhibitors' resistance in acquired EGFR inhibitor-resistant lung cancer cells (42, 62, 63) . These results implicate that the YAP is closely related to the EGFR inhibitor resistance development and might itself be a critical therapeutic target. Therefore, a pre-clinical analysis with a YAP inhibitor and an EGFR inhibitor is needed to validate the ability of such regimen to overcome the EGFR inhibitor resistance in cancer therapy.
Breast cancer
Breast cancer is the most common cancer type among US-American women with one out of eight developing it. A breast cancer is a malignant tumor arising from the cells of the breast (64) . There are many breast cancer types that differ in their capability of spreading (metastasize) to other body tissues. Breast cancer can be classified by the tumor's site of origin, the stroma surrounding the gland, or the ability to grow in the lumen of the gland (64) . Breast cancer cells have receptors on their surface as well as in their cytoplasm and nucleus (64) . Chemical messengers such as hormones bind to receptors which causes cell changes. Breast cancer cells may or may not have three important receptors: Estrogen receptor (ERs), Progesterone receptor (PRs), and Human epidermal growth factor receptor 2 (HER2). The most common forms of breast cancer can be classified into hormone hormonereceptor-positive breast cancer (involving estrogen and/or progesterone), HER2-positive breast cancer, and breast cancers that are negative for all three receptors (triple-negative breast cancer [TNBC]) (54, 64) . In this review, we demonstrated that the hyper-activation of YAP in breast cancer tissues related directly to the PR status, a luminal subtype, and inversely with HER2 and Ki67 levels. TAZ, as the paralog of the YAP, also plays an important role in the tumorigenesis of breast cancer cells and is overexpressed in about 20% of all human breast cancers (54) . In breast cancer, the hyper-activation of a YAP/TAZ-transcriptional program feeds various tumorigeneses (36, 54) . An important oncogenic function of TAZ relates to its association with BC stem cells (BCSCs) (65) (66) (67) (68) . In particular, several studies reported a connection between TAZ and the self-renewal of BCSCs (66, 68, 69) . However, several recent controversial results showed that mention relates to the biological significance of YAP in breast cancer. The YAP regulation has shown opposite or different results (70, 71) . There are directly opposing ideas about the tumor-promoting function of YAP that are, in turn, countered by some clinical http://bmbreports.org BMB Reports evidence, at least with regard to triple-negative BCs (36, 54). Indeed, another research group has recently reported the relation between a reduced YAP expression/activation and decreased recurrence-free survival in luminal tumors (50, 53, 72) . This clinical evidence supports that, at least in TNBC, YAP may possess an oncogenic character. It is plausible that a YAP acts differently in a distinct breast cancer class. The growing interest in YAP related to breast cancer has promoted a wave of research on other breast cancer subtypes. The results from these studies will explain the exact mechanisms underlying the clinical significance of YAP/TAZ in individual breast cancer subtypes.
Colon cancer
Colorectal cancer (CRC) remains a leading cause of cancer death, with one million new cases each year worldwide and as many as half a million cancer deaths annually. The disease begins as a benign adenomatous polyp which develops into an advanced adenoma with high-grade dysplasia and then progresses to an invasive cancer. The development of colorectal cancer (CRC) involves the accumulation of genetic alterations and epigenomic changes that affect cell growth, cell death, and the tumor's microenvironment (73, 74 
Stomach cancer
Stomach cancer, also called gastric cancer, is a cancer that derives from the glandular epithelium of the stomach. These gastric cells can grow into a tumor. It has been reported that increased YAP mRNA and protein levels in gastric cancers are correlated with metastases, the cancer stage, and poor outcomes for the patients (88) (89) (90) . In addition, the expression of YAP target genes and of YAP mRNA itself was elevated in a preclinical model of gastric cancer, generated by an infection with helicobacter pylori which is a common risk factor for stomach cancer development in humans (18). VGLL4 is a natural antagonist of YAP and its TDU region suffices for a YAP inhibition, allowing the development of a peptide-based YAP inhibitor (18, 47). This peptide drug strongly inhibits stomach cancer growth which presents an opportunity for treating gastric cancer. Such a peptide drug development strategy can be extended to YAP-dependent cancer types. (91, 92) . For successful developments of YAP inhibitor strategies, a human cancer must be depend on the Hippo pathway-YAP in targeted therapy. The co-crystal structure of the YAP-TEAD binding domain was identified (52, 93, 94) . and therefore, disrupting YAP transcriptional mechanisms block the interaction of YAP to TEAD binding. Verteporfin (VP) which is a FDA-approved photosensitizing small molecule compound used in the photodynamic therapy of neo-vascular macular degeneration that blocks YAP-TEAD binding was identified by the John Hopkins Drug Library via high-throughput screening (85) . VP inhibited liver overgrowth resulting from the overexpression or hyper-activation of YAP by silencing Hippo kinase components.
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PART 2. THE HIPPO PATHWAY -YAP AS A POTENTIAL THERAPEUTIC ANTI-CANCER TARGET
Another strategy of YAP-TEAD inhibition involves an inhibitor peptide competing with the YAP for TEAD binding. The inhibitor peptide was identified in the TDU domain of VGLL4, a YAP antagonist, which potently inhibits the YAP-dependent tumorigenic potential of gastric cancer cells, both in vitro and in vivo (18, 47) . This VGLL4-mimicking peptide, which was designed with a VGLL4 sequence, interacts with TEAD in a way that excludes YAP. In sum, such results demonstrate that the pharmacological intervention with a YAP-TEAD complex formation is a potential therapeutic approach with few side effects.
DISCUSSION
Many study results provide evidence for the Hippo pathway component's role in cancer development and in the elevated expression or hyper-activation of YAP in human tumors regarding various aspects of cancer biology at the cell and tissue level. A dysregulation of this mechanism is unlikely to explain the YAP activation in cancers. For example, with the exception of NF2, mutations of upstream Hippo components are rarely found in cancers. In addition, not a single case of a YAP mutation by itself has been reported. The mRNA level of YAP correlates with target gene expressions and cancer progressions. This YAP activity is strongly related to cancer development and anti-cancer drug resistance. During the past few years, our knowledge of the Hippo pathway in both mice and humans has largely increased. Also, important drugs were proven to modulate the YAP and the development of new medications in pre-clinical trials and genetic mouse models is ongoing. The YAP may represent an essential molecular target for cancer therapy, although further research is underway to identify other YAP regulators. Particularly the inhibition with a YAP-TEAD complex is of central interest in the development of new anti-cancer drugs. Since the YAP-TEAD complex is regulated by a protein-protein interaction (PPI) which could serve potentially as a target for inhibition, more selective PPI drugs might also be needed to treat cancer patients. VP as a drug already approved by the FDA could serve as reference to develop new YAP inhibitors. Finally, several promising novel YAP inhibitors are currently pre-clinically tested and may soon be subjected to clinical trials. http://bmbreports.org 
